Teaching Doctors Nationwide How to Recognize & Differentiate Between Lyme Disease, COVID-19 & the Flu in Quidel-Hosted May 5 ...
April 27 2021 - 9:00AM
Business Wire
With Lyme disease season emerging and the COVID-19 pandemic
still with us, an important webinar designed to help physicians
differentiate between the two (as well as the flu) so as to provide
timely diagnosis and treatment for their patients will be held on
Wednesday, May 5. The webinar is the latest in an ongoing series
sponsored by Quidel, the California-based diagnostic health care
manufacturer known for successfully developing rapid diagnostic
health solutions.
Titled "Solve the Great Imitators: Is it COVID-19, Tick-Borne
Disease or the Flu?," the webinar will be conducted by Sean
McCloy,* M.D., M.P.H., M.A., national thought leader and medical
director at the Integrative Health Center of Maine in Portland
where he practices family medicine with an expertise in Lyme
disease. The free educational program, being held in collaboration
with the Global Lyme Alliance, will take place at noon EDT.
Registration is available at Quidel x GLA Lyme Webinar
Registration.
“Lyme disease is often misdiagnosed because its symptoms often
mimic other conditions like the flu and many others. As we enter
peak tick season, it is important to remind health care providers
and others about the importance of screening their patients for
Lyme disease,” says Sara Tyghter, director of education and
outreach at Global Lyme Alliance.
“The trio of acute COVID-19 infection, tick-borne disease and
influenza infection all have very similar presentations and share
the common symptoms of fever/chills, fatigue, muscle aches and
headaches,” says Dr. McCloy. “That makes it both challenging and
critical for health care professionals to properly distinguish one
from the other so that they can correctly treat their patients for
the corresponding ailment. During the webinar, we’ll discuss the
often subtle differences in how these illnesses affect patients and
will review diagnostic options that will help physicians make
point-of-care decisions so that their patients can get timely
treatment and feel better quickly.”
As the weather heats up during spring and summer, McCloy says
that it is particularly important to test for Lyme disease, which
afflicts as many as 400,000 Americans each year and can lead to a
number of serious life-threatening problems if not caught early.
“Fortunately, new tools are now available to make it easier to test
for Lyme disease quickly and accurately,” he says. “The best tool I
have found and one which has revolutionized the speed and accuracy
for diagnosing Lyme disease is the Sofia® 2 Lyme FIA test by
Quidel.”
The Sofia 2 Lyme test provides the patient and physician with
indicative results within 15 minutes, as opposed to days, which has
historically been the norm. Performed in the privacy of a doctor’s
office or local clinic, it is also the only test that can get
results from a simple finger prick of blood. “Not having to wait
days for test results allows clinicians to more rapidly treat those
patients with positive results while more quickly pursuing other
diagnosis and treatment for those who test negative,” says
McCloy.
Among those expected to attend the free May 5 webinar are
physicians; allied health professionals; health researchers; and
representatives of physician offices, laboratories, urgent care
centers and others interested in the subject.
*Dr. McCloy receives an honorarium for conducting the webinar
sponsored by Quidel.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of
diagnostic solutions at the point of care, delivering a continuum
of rapid testing technologies that further improve the quality of
health care throughout the globe. An innovator for over 40 years in
the medical device industry, Quidel pioneered the first FDA-cleared
point-of-care test for influenza in 1999 and was the first to
market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted
brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®,
Quidel’s comprehensive product portfolio includes tests for a wide
range of infectious diseases, cardiac and autoimmune biomarkers, as
well as a host of products to detect COVID-19. With products made
in America, Quidel’s mission is to provide patients with immediate
and frequent access to highly accurate, affordable testing for the
good of our families, our communities and the world. For more
information about Quidel, visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210427005457/en/
Jim Yeager 818.264.6812 (mobile) jim@breakwhitelight.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024